Biogen

As many as 5 million people globally live with a form of lupus. However, there has been limited progress toward bringing new treatment options to patients. Our ongoing research aims to change that. Read more from STAT: https://ow.ly/awHw50Uc74v

Earlier this week, we announced that our ophthalmology biosimilar developed with Samsung Bioepis received approval from the European Commission. This is our fifth biosimilar approved in Europe, growing our portfolio of biosimilar options to help benefit more patients. https://lnkd.in/eWfVPi22   #News | #Biogen | #Ophthalmology  

We’re proud to be at ACR Convergence 2024, sharing the latest research updates from our robust lupus pipeline. Through our commitment to diversity in our lupus clinical trials, and by exploring novel approaches to treatment, we aim to truly transform lives. Learn more about our work: https://ow.ly/FIc450U9XiY   #ACR24 | #Lupus 

At ACR Convergence 2024, along with UCB, we shared detailed results from a Phase 3 study of our investigational therapy for moderate-to-severe systemic lupus erythematosus (SLE). Read more: https://ow.ly/TIYn50U9WFM #News | #Lupus | #ACR24

We’re committed to contributing to the future of Alzheimer’s disease through innovative research and clinical trials. This Alzheimer's Awareness Month, our Alzheimer’s and Dementia Disease Unit lead, Diana Gallagher, shares what drives her passion for our work and emphasizes the profound impact we can have on patients and families living with Alzheimer’s disease.    Learn more about our ongoing efforts in Alzheimer’s disease research here: https://ow.ly/BB0y50U9hXC   #AlzheimersAwarenessMonth | #AlzheimersDisease | #Alzheimers 

There are around 5 million people worldwide who are living with lupus, a complex chronic autoimmune disease that can cause pain and inflammation in any part of the body. In partnership with the scientific community, we aim to advance research to address the diverse needs of the lupus community. Learn more about our work: https://ow.ly/8wnI50U86WF    #ACR24 | #Lupus 

The updates we are sharing at ACR Convergence 2024 represent our ongoing commitment to advancing options that can make a difference in the lives of people living with lupus. Learn more about our long-standing efforts in lupus: https://ow.ly/Wns750U86Pn     #ACR24 | #Lupus 

With Eisai, we received a positive opinion from the Committee for Medicinal Products for Human Use, part of the European Medicines Agency, in our treatment for Alzheimer's disease (AD). This represents a significant advancement in our commitment to people living with AD.     Read more in our news release: https://lnkd.in/daj5mnAk #News | #AlzheimersDisease

Alzheimer’s disease is a progressive neurological illness that impairs thinking and the independence of millions of people worldwide. Click through to read how Normajo has been navigating the complexities of this disease as a caregiver: https://ow.ly/cllY50U71rB   #AlzheimersDisease | #NationalFamilyCaregiversMonth  

Lee Gervitz, our Vice President and Head of North America Medical will be at The Boston Globe’s Future of Medicine event with industry leaders to discuss advancements of Alzheimer’s disease (AD) research and how the healthcare system is evolving to serve people living with AD.     Learn more about this event: https://ow.ly/qJOs50U61gN